Huang Shan Shi

Researchers are establishing a standardized clinical database for patients with liver cancer, including hepatocellular carcinoma and related types, to support high-quality real-world clinical studies. This observational study is led by the Department of Hepatobiliary Surgery at the First Affiliated Hospital of the University of Science and Technology of China USTC in collaboration with multiple centers nationwide. The purpose is to collect detailed clinical information to better understand liver cancer outcomes over time. Participants will receive routine clinical treatments for liver cancer, such as surgical resection, ablation, transarterial chemoembolization TACE, hepatic arterial infusion chemotherapy HAIC, and various anti-tumor drugs including immunologic, targeted, and chemotherapy agents. The study observes and records these standard treatments without assigning interventions. The research will track these patients in a cohort database to monitor their treatment and progression. During the study, participants will be followed for up to 10 years to assess overall survival, recurrence-free survival, and survival time after cancer recurrence. Researchers will collect blood and surgical tissue samples and perform regular follow-up visits to gather clinical data and pathology results. This long-term monitoring aims to provide comprehensive insights into liver cancer progression and treatment outcomes.

Gallstone disease is common in China, affecting about 15% of the population, with 210 million people affected. Acute cholecystitis, a sudden inflammation of the gallbladder often caused by gallstones, can lead to serious complications such as gallbladder perforation and high mortality if untreated. This study investigates the effects of single-incision laparoscopic cholecystectomy SILC compared to conventional laparoscopic cholecystectomy CLC on patient outcomes after surgery for acute cholecystitis, aiming to improve quality of life and reduce pain and scarring. The trial compares two surgical methods SILC, which uses a single incision through the navel, and CLC, which involves three or four small incisions. Both groups may switch to open cholecystectomy if the surgery is difficult to complete. The study is randomized and triple-blinded to ensure unbiased results. Researchers want to establish a standardized procedure for SILC in treating acute cholecystitis and evaluate its safety and impact on postoperative recovery. Participants will be followed for three years to assess the time it takes to return to normal life, the cosmetic results of surgery, postoperative pain, scar quality, and any complications. The study includes regular monitoring and evaluation to measure these outcomes and ensure participant safety. This long-term follow-up will provide valuable information on the effectiveness and patient experience with SILC compared to traditional laparoscopic surgery.

Researchers are evaluating the safety and effectiveness of edaravone dexborneol sublingual tablets for treating cognitive problems after a stroke in adults aged 40 to 80 years. This exploratory Phase II clinical trial is randomized, double-blind, and placebo-controlled, aiming to compare outcomes between patients receiving the study drug and those receiving a placebo. The study focuses on patients who have had an acute ischemic stroke and developed cognitive impairment. Participants will be randomly assigned to receive either edaravone dexborneol sublingual tablets or a placebo twice daily for 24 weeks. Both groups will follow the same treatment schedule over this period. The trial will monitor and compare the safety and effectiveness of the tablet by assessing cognitive function and other health measures. During the study, participants will undergo evaluations including cognitive tests such as the Vascular Dementia Assessment Scale-cognitive subscale, Mini-Mental State Examination, and Montreal Cognitive Assessment at various times up to 24 weeks. Researchers will also track adverse events, treatment discontinuations, and other stroke-related scales. The total follow-up period for safety monitoring extends to 26 weeks, including after treatment completion or early withdrawal.

Researchers are evaluating the effectiveness and safety of HSK39297 tablets in adults with primary IgA nephropathy IgAN, a kidney condition. This is a Phase 3 study sponsored by Haisco Pharmaceutical Group Co., Ltd. The trial aims to understand how HSK39297 impacts kidney function and protein levels in urine compared to placebo in patients diagnosed with IgAN confirmed by biopsy within the last ten years. Participants will be randomly assigned to receive either HSK39297 at a dose of 200 mg once daily or a placebo, both given for a fixed treatment period of 48 weeks. The study is double-blind, meaning neither the participants nor researchers know who receives the active drug or placebo during the trial. The primary treatment period lasts 48 weeks, during which participants take the assigned tablets daily. During the study, participants will have regular visits to monitor kidney function through urine protein to creatinine ratio measured from 24-hour urine collections and estimated glomerular filtration rate eGFR. These measures will be assessed up to 48 weeks and even up to 104 weeks for some outcomes. Safety will be monitored throughout the study period, which can last up to 108 weeks, including tracking any adverse events. Participants will be asked to comply with scheduled lab tests and visits to support thorough evaluation of the treatment effects and safety.

Researchers are investigating whether adding endovascular therapy EVT to best medical management benefits patients with minor acute ischemic stroke who experience early neurological deterioration END due to large vascular occlusion LVO in the anterior circulation. The study focuses on patients presenting more than 24 hours after stroke onset, a late treatment window, where the effectiveness of EVT is not well known. The goal is to assess the safety and efficacy of EVT in this specific group of patients. The study randomly assigns approximately 272 patients aged 18 years and older with minor stroke and LVO to one of two groups. One group receives best medical management alone, which includes standard therapies like monitoring vital signs, managing blood pressure, glucose, lipids, and antithrombotic treatment as appropriate. The other group receives best medical management plus EVT, which may include mechanical or aspiration thrombectomy, intra-arterial thrombolysis, angioplasty, or stenting, chosen by local interventionalists. Treatment is given after randomization, which occurs more than 24 hours after stroke onset. Participants will have seven study visits, including at randomization, 24, 48, and 72 hours after, at 7 days or discharge, and at 30 and 90 days post-randomization. Data collected include demographics, symptoms, lab tests, neuroimaging, and neurological function scales. The main outcome measures are the proportion of patients achieving a good clinical outcome at 90 days, assessed by the modified Rankin Scale, along with safety outcomes like intracranial hemorrhage and mortality. A Data and Safety Monitoring Board oversees participant safety throughout the trial.